| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 248.88% | Citigroup | $4 → $3 | Maintains | Buy |
| 06/30/2023 | 481.46% | Baird | $3 → $5 | Maintains | Outperform |
| 09/07/2022 | 5482.04% | BTIG | $57 → $48 | Maintains | Buy |
| 08/09/2021 | 3039.9% | Citigroup | $26 → $27 | Maintains | Buy |
| 04/03/2020 | 3737.66% | Wedbush | $35 → $33 | Maintains | Outperform |
| 01/22/2020 | 3505.07% | Ladenburg Thalmann | $28 → $31 | Maintains | Buy |
| 06/26/2019 | 2458.44% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 01/29/2019 | 5365.75% | Baird | → $47 | Initiates Coverage On | → Outperform |
What is the target price for Eiger BioPharmaceuticals (EIGR)?
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $3.00 expecting EIGR to rise to within 12 months (a possible 248.88% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eiger BioPharmaceuticals (EIGR)?
The latest analyst rating for Eiger BioPharmaceuticals (NASDAQ: EIGR) was provided by Citigroup, and Eiger BioPharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for Eiger BioPharmaceuticals (EIGR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eiger BioPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eiger BioPharmaceuticals was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
Is the Analyst Rating Eiger BioPharmaceuticals (EIGR) correct?
While ratings are subjective and will change, the latest Eiger BioPharmaceuticals (EIGR) rating was a maintained with a price target of $4.00 to $3.00. The current price Eiger BioPharmaceuticals (EIGR) is trading at is $0.86, which is out of the analyst's predicted range.
Today, after hitting the high near 24,000 in the early session and entering bearish positions, the index fell sharply by nearly over 600 points, immediately recouping yesterday's losses significantly.
Moreover, today it broke the new high again, reaching a maximum of 24,076, but by the end of the market, it fell back by about 70 points, producing a bearish candle. The current trend has not yet been broken, but from the previous low until now, it has risen close to 6,000 points. It is believed that those with positions can continue to hold until there is a clear trend reversal for profit-taking. Those without positions can wait for a pullback to get in. Actually, it is hoped for a quick pullback, as it allows for entry and also provides a healthy breath.
Currently, the outlook remains the same as before. It is believed that even if there is a pullback, it shouldn't be too deep. However, if Futures fail to stabilize and close below 22,350, there may still be room for decline. The chance of Futures falling below 21,400 in the short term should be low, so it is considered that if a significant pullback occurs, it presents a good opportunity to incrementally go long. Recently, there has been a consistent approach to not hold positions overnight, only focusing on immediate trades, as there is no high chasing and no casual short selling.
Comment(0)
Reason For Report